Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Foa

Showing results (81-90 of 82) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 82 results.
British Journal of Haematology|December 3, 1999
Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO)E Di Bona, F Rodeghiero, B Bruno, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trialM G Ghi, A Paccagnella, D Ferrari, et al.
Pageof 9

Showing results (81-90 of 82) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 82 results.
British Journal of Haematology|December 3, 1999
Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO)E Di Bona, F Rodeghiero, B Bruno, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trialM G Ghi, A Paccagnella, D Ferrari, et al.
Pageof 9